Humana Inc. (NYSE:HUM) experienced a sharp decline in its stock price on Wednesday, falling 6.8% to $362.16 near the close, even after reporting second-quarter earnings that exceeded analyst expectations. The market's reaction was driven by the company's strategic decision to overhaul its Medicare Advantage offerings, a move that will result in the departure of approximately 600,000 members by 2027.
Restructuring Details and Impact
The planned market exits, set to take effect in 2027, represent 9.3% of Humana's 6.454 million individual Medicare Advantage members as of June. This figure also accounts for 49.8% of the 1.204 million members added since December. Humana anticipates recapturing roughly 40% of these departing members, or nearly 240,000, through alternative plans. However, the expected churn underscores management's commitment to prioritizing margin restoration over membership growth. The company is targeting a stable pretax Medicare Advantage margin of at least 3% by 2028.
Quarterly Financial Performance
Despite the strategic headwinds, Humana's second-quarter results were robust. Consolidated revenue surged 26.2% year-over-year to $40.87 billion, while adjusted earnings per share (EPS) rose 21.4% to $7.61, surpassing the LSEG consensus estimate of $7.22. However, the company maintained its full-year adjusted EPS guidance at a minimum of $9.00, which disappointed some investors who had hoped for an upward revision following the strong quarter. The insurance benefit ratio, which measures the portion of premiums spent on medical care, deteriorated by 1.3 percentage points to 91.2%, reflecting higher costs from new enrollees and reduced revenue from Star ratings. Conversely, the adjusted operating-cost ratio improved by 1.2 percentage points to 9.7%, indicating that scale benefits are helping to control overhead expenses.
Market Context and Analyst Commentary
Barclays analyst Andrew Mok noted that the results "likely fell short of elevated investor expectations," especially given that Humana's shares had risen approximately 60% over the past three months. The broader market context also played a role, as peer UnitedHealth Group Inc. (NYSE:UNH) had raised its 2026 guidance on July 16 following improved expense management, setting a higher bar for Humana. Humana's decision to keep its main forecast unchanged contrasted with UnitedHealth's positive outlook, further weighing on investor sentiment.
Forward Guidance and Star Ratings
Looking ahead, Humana lowered its reported GAAP EPS minimum to $6.52 from $8.36, reflecting the anticipated impact of the restructuring. The company expects third-quarter adjusted EPS to be close to negative $1.00, with the insurance benefit ratio projected to rise just above 94%. Chief Executive Jim Rechtin stated that "the first half of the year went well," aligning with management's expectations set during the previous year's investor day. However, Star ratings remain a critical factor, as the Centers for Medicare & Medicaid Services (CMS) calculates 2026 ratings to determine quality-bonus payouts for 2027. Humana's initial estimate in October suggested that 20% of its members are enrolled in plans rated four stars or above, and the company believes diversification across contracts will help mitigate risk for that payout year.
Risks and Key Milestones
Several risks persist, including the possibility that Humana may not recapture as many members as expected, medical costs could outpace pricing, and uncertainty around Star thresholds may delay margin recovery. The company's next scheduled milestone is a virtual investor update on December 10, where further details on the 2027 plan are likely to be discussed. In the meantime, the composition of the 2027 plan holds greater significance for investors than the latest quarterly outperformance.
